Clinical Trial Update: Efficacy of Decitabine in Clearance of MRD [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating decitabine for clearance of minimal residual disease in acute myeloid leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Decitabine (Decitabine)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: AML | Phase 1, Phase 2 | Status: WITHDRAWN